On November 17, Legend Biotech fell 5.29% in Regular Trading, trading at $16.595 per share, with turnover of $20.5456 million.
The move was linked to continued post-earnings selling pressure after Evercore ISI downgraded the stock to In Line and set a $20 price target, extending a broader wave of analyst target cuts following the company’s latest quarterly report.
In its recent results, Legend Biotech reported third-quarter net profit of $51.7 million, reversing a year-earlier loss, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue of $359.5 million came in slightly below market expectations near $361.5 million. After the report, RBC, Morgan Stanley, Oppenheimer and Barclays also lowered price targets, indicating a more cautious near-term stance on growth and valuation despite solid product sales momentum.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments